MicuRx Pharmaceuticals, Inc.
  • About MicuRx
    • Our company
    • Our Team
    • Vision & mission
    • History
    • Contact Us
  • Scientific research
    • Antibiotic Resistance
    • Kidney Disease
    • MicuRx R&D
    • Publications
  • Pipeline
  • Newsroom
    • Corporate news
  • Careers
  • Contact Us
  • 中
  • New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile

    Time:2014-05-13  /  View:729 times
    Prev: Selection and characterization of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I
    Next: Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes
    Back

    Copyright © 2025 All Rights Reserved MicuRx

    Medical Representative Recordation Platform 沪ICP备12020812号

    MicuRx Pharmaceuticals, Inc.